Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
Authors:
Open Access
- 5 April 2021
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 19 (7) , 1687-1696
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 22 references indexed in Scilit:
- Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial resultsBlood, 2019
- Hemophilia and inhibitors: current treatment options and potential new therapeutic approachesHematology-American Society Hematology Education Program, 2016
- Tissue Factor Pathway InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2016
- Toward optimal therapy for inhibitors in hemophiliaBlood, 2014
- Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulationProceedings of the National Academy of Sciences, 2013
- Factor VIII inhibitors in hemophilia A: rationale and latest evidenceTherapeutic Advances in Hematology, 2012
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia modelBlood, 2012
- Tissue factor pathway inhibitor: structure-functionFrontiers in Bioscience-Landmark, 2012
- Haemophilias A and BThe Lancet, 2003